Boston Scientific Corp. continues to prove out its strategy of active acquisitions combined with industry-leading organic growth with the closing of its $88 million acquisition of Elutia Inc.’s Bioenvelope business and very positive targets for growth presented during its investor day on Sept. 30.
Many patients who survive myocardial infarction go on to experience heart failure. Researchers at Qilu Hospital of Shandong University found that bone morphogenetic protein 1 (BMP1) was upregulated in patients after myocardial infarction, as well as in a mouse model of the same condition.
CSPC Pharmaceutical Group Ltd. has obtained clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials in China with SYH-2070 injection, a double-stranded small interfering RNA (siRNA) drug for the treatment of hypertriglyceridemia or mixed hyperlipidemia.
Ernst & Young LLP didn't quite declare the patient cured but saw signs of a strong med-tech recovery after a few years on life support in its annual Pulse of the MedTech Industry report. The global accounting giant particularly called out strength in the cardiovascular, diabetes, robotics and orthopedics segments.
Roche Holdings AG reported results from its TSIX study which demonstrated that its sixth-generation Troponin T test is accurate at diagnosing heart attacks not only in men but also women. Recently granted CE mark, the Elecsys Troponin T hs Gen 6 test, demonstrated it was able to identify acute myocardial infarction (AMI) and identify those not having an AMI, with a high level of precision, ensuring that patients receive the care they need at the earliest opportunity.
Novo Nordisk A/S terminated its global licensing deal with Japan’s Heartseed Inc. for its allogeneic induced pluripotent stem cell (iPSC)-derived cardiomyocytes.
Scientists at Unity Health Toronto and University of British Columbia have identified aeroplysinin derivatives reported to be useful for the treatment of asthma, atherosclerosis, autoimmune disease, diabetic nephropathy and more.
In heart failure, the heart does not oxygenate body tissues adequately. A standard treatment is SGLT2 inhibitors such as empagliflozin and dapagliflozin, derived from the national product phlorizin. However, long-term use of these inhibitors increases risk of renal damage and euglycemic diabetic ketoacidosis.
Tevard Biosciences Inc. has presented new preclinical data on the use of therapeutic suppressor tRNAs (suptRNAs) for the treatment of Duchenne muscular dystrophy (DMD) and dilated cardiomyopathy (DCM). The data show potent restoration of full-length functional proteins in models of DMD and DCM caused by titin truncations (DCM-TTNtv).
A month after raising $55 million to advance its AI-enhanced ultrasound diagnostics for cardiovascular disease, Ultromics Ltd. presented strong results for its U.S. FDA-cleared AI analysis of echocardiograms at the American Society of Echocardiography's 2025 Scientific Sessions in Nashville, Tenn. Ultromics' Echogo Amyloidosis was able to detect cardiac amyloidosis earlier and more accurately than traditional methods, missing fewer cases without increasing unnecessary testing.
RSS
